

# CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

NCT06822881

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Beijing GoBroad Hospital
<b>Enrollment</b>	27 participants

## Key Eligibility Criteria

---

### Inclusion (33)

- Voluntary signing of the Informed Consent Form (ICF)
- Age range: At the time of signing the ICF, the age is between 18 and 60 years old (including 18 and 60 years old), regardless of gender.
- No systemic active infection within 2 weeks before screening.
- Contraceptive requirements for participants with child - bearing potential.
- <!-- -->

... and 28 more (see full listing online)

### Exclusion (25)

- Previous history of CAR-T cell or other genetically modified T-cell therapies, or previous major organ transplantation.
- Use of B-cell targeted drugs (such as rituximab) within 2 months before screening.
- Allergy or intolerance to lymphodepletion drugs, tocilizumab, or life-threatening allergic reactions, hypersensitivity reactions, or intolerance to the CT1190B preparation or its excipients, or a history of other severe allergies such as anaphylactic shock.
- Use of corticosteroids e 10 mg/day of prednisone (or equivalent drug) within 10 days before the infusion of CT1190B.
- Use of immunosuppressive agents that affect T-cells (mycophenolate mofetil, methotrexate, cyclosporine, azathioprine, leflunomide, tacrolimus) within 10 days before the infusion of CT1190B.

... and 20 more (see full listing online)

## Locations (1 total)

---

Beijing GoBroad Hospital, Beijing, Beijing Municipality, China